The main mechanism of CsA inhibition of T-cell activation is by blocking calcineurin-dependent NFAT transcriptional activation. Activation-induced cell death is an essential process for T-cell development and function, which can be affected by the nature of the initial stimulating events.
46 The concentration-dependent CsA modulation of T-cell fate has been demonstrated in several studies. It was shown that Jurkat or PBMC activated with OKT3 (anti-CD3) and restimulated after 6 days with PMA and ionomycin underwent apoptosis, which was inhibited by CsA (approximately 83 nM) after 72 hours.
47 CsA at the concentration attained in rodents (10 μM) elicited T-cell apoptosis by 24 hours via release of preformed TGFβ1, independent of calcineurin inhibition.
48 Additionally, the sensitivity of T cells to CsA depends on activation of other transcriptional pathways such as MAPK and NF-κB. Jurkat cells expressing active NFAT alone are sensitive to CsA, whereas coexpression of a constitutively active NFAT and MEKK1 renders T cells' resistance to CsA (calcineurin-independent).
49 Activated T-cell death appeared to be prevented by a survival signal afforded by NF-κB.
50 In the current study, Jurkat activation and IL-2 production induced by PMA/αCD3 was inhibited by subnanomolar CsA (
>1 nM). At 5 to 10 μM, CsA promoted resting T-cell death, and exacerbated activated T-cell death. At all concentrations tested (10 nM–10 μM), CsA was not able to prevent MPTP opening. Additionally, it was reported that IL-2 production in Jurkat was caspase-mediated.
41 Our study has revealed that CsA hindered the effect of caspase inhibitors, thus facilitating activation-induced T-cell death, suggesting a calcineurin-dependent mechanism of CsA action, rather than cytotoxicity. Nevertheless, CsA at a broad concentration range used in the current studies exerted no protection for MPTP opening in Jurkat, and had a minimal effect on primary human blood CD3
+ T cells. This may be attributed to a lower mitochondrial content in T lymphocytes compared with epithelial cells. Cells of the immune system have few mitochondria in general.
51 Additionally, different OS inflammatory disorders are characterized by different types of activated T cells. The outcome of the immune activation state in the ocular tissue microenvironment is likely a result of the accumulative response from various T-cell subtypes, as well as their communications with ocular resident cells. CsA has been used for treating dry eye, allergic conjunctivitis, and rheumatoid arthritis (RA), where T
H1, T
H2, or T
H17 exhibits a prominent role in the disease pathogenesis, respectively. However, CsA action on various T-cell subsets including effector as well as suppressive T cells has not been fully studied. It is to be determined if CsA differentially regulates MPTP response under different inflammatory conditions for T
H1, T
H2, and T
H17, as well as for suppressive T regulatory cells. It is also imperative to note that most of the experiments in the current report were conducted using the immortalized cell lines. Although IOBA-NHC cells resemble some crucial characteristics of human conjunctival epithelium,
34 caution should be taken when extrapolating in vitro findings to presume the MPTP status in OS pathology in humans. Therefore, our models remain an experimental tool that helps to serve as a basis for studying mechanism pathways and conducting in vivo studies. Experiments are being performed to establish an epithelial and T-cell coculture to determine MPTP response during their interactions under normal and inflammatory conditions. Mitochondrial involvement in animal models of ocular inflammation such as dry eye will also be investigated.